2nd LNP Characterization and Analytical Development Summit

Kongressthemen
Turbocharged by increased LNP pipeline development and technological advancements with SPARTA biodiscovery raising $4.3m for their characterization technology, UPENN engineers developing CAR-T therapies, and Genevant securing a $114m deal with Tome. As the industry places a greater emphasis on later-phase assets, understanding the intricacies of LNPs and investing in analytical assays are becoming essential for ensuring market confidence.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
URL:
Brochure: https://go.evvnt.com/2555692-3?pid=4832

Speakers: Benjamin Hall, Senior Scientist - Analytical Development, Tessera Therapeutics, Carlo Zambonelli PhD, Independent Expert, and more

https://go.evvnt.com/2555692-2?pid=4832

Frau Stephanie Nketia